On June 22, the official website of the National Medical Products Administration (NMPA) showed that Chongqing Genrix Biopharmaceutical Co., Ltd.’s Silevimig Injection (GR1801) has been approved for marketing for post-exposure passive immunization in adults with suspected rabies virus exposure. Silevimig is the world’s first bispecific antibody for rabies passive immunization.
Silevimig is a recombinant fully human anti-rabies virus (RABV) bispecific antibody independently developed by Genrix. It is classified as a Class 1 therapeutic biological product, targeting the envelope glycoprotein (G protein) of RABV. This bispecific antibody features a scFv+Fab structure, utilizing KIH technology to address heavy chain mispairing and scFv fusion technology to address light chain mispairing. By targeting and binding to G protein epitopes I and/or III, it blocks the binding to its receptor, thereby preventing viral neural infection before the active immunity from the rabies vaccine fully takes effect, thus preventing rabies. The molecular design of Silevimig meets the WHO’s recommendation for anti-rabies virus antibody development—using a "cocktail" combination of multiple monoclonal antibodies targeting different antigenic sites to ensure efficacy against different viral strains or genotypes.